Mark Lappe co-founded Inhibrx in 2010 and has served as Chief Executive Officer since its inception. He also serves as the Chairman of the board of directors. Mark has extensive expertise in the biotechnology industry with over 30 years of experience in executive management, investment management, and executive recruiting, having built the executive teams of over 40 start-up biotechnology and medical device companies. Prior to founding Inhibrx, Mark was the founder and Managing Partner of Efficacy Biotech Fund, a fund focused on strategic investment in public biotechnology companies.
1:45 PM - 2:45 PM (PDT)
Wednesday, June 15
The panel will explore the question as to whether crossover rounds are still needed to enter the U…